Top

Published in:

01-05-2007 | Review Article

Risk-adapted strategy for the management of febrile neutropenia in cancer patients

Authors: Jean Klastersky, Marianne Paesmans, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles

Published in: Supportive Care in Cancer | Issue 5/2007

Abstract

Background

Among patients who develop fever and neutropenia after having received cancer chemotherapy, we have to distinguish at least three categories of risk levels for complications and death: patients at low risk and eligible for oral treatment and possibly outpatient management, patients at low risk who require intravenous therapy, and patients at higher risk.

Results and discussion

The Multinational Association for Supportive Care in Cancer scoring system identifies patients at low risk (<5%) of severe complications with very low mortality (<1%) during an episode of febrile neutropenia; this group represents roughly 70% of an unselected population of patients with febrile neutropenia. A significant percentage (≈50%) of these patients are eligible for treatment with orally administered antibiotics and can be discharged early and safely from the hospital after a short (24–48 h) observation period.

Innes HE, Smith DB, O’Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 89:43–49PubMedCrossRef

Vento S, Cainelli F (2003) Infections in patients with cancer undergoing chemotherapy: aetiology, prevention and treatment. Lancet Oncol 4:595–604PubMedCrossRef

Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed

Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed

Talcott JA, Whalen A, Clark J et al (1994) Home antibiotic-therapy for low-risk cancer patients with fever and neutropenia—a pilot-study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114PubMed

Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560PubMedCrossRef

Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef

Malik IA, Khan WA, Karim M et al (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia—results of a prospective randomized trial. Am J Med 98:224–231PubMedCrossRef

Rubenstein EB, Rolston K, Benjamin RS et al (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640–3646PubMedCrossRef

10.

Elting LS, Rubenstein EB, Rolston KVI et al (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247–259PubMed

11.

Kern WV, Cometta A, De Bock R et al (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341:312–318PubMedCrossRef

12.

Freifeld A, Marchigiani D, Walsh T et al (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–311PubMedCrossRef

13.

Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561–2568PubMedCrossRef

14.

Adams JR, Angelotta C, Benett CL (2006) When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective ? J Clin Oncol 24:2975–2976PubMedCrossRef

15.

Klastersky J, Paesmans M, Georgala A et al (2006) Management with oral antibiotics in an outpatient setting of febrile neutropenic cancer patients, selected on the basis of a score predictive for complications. J Clin Oncol 24:4129–4134PubMedCrossRef

16.

Klastersky J (1983) Empiric treatment of infections in neutropenic patients with cancer. Rev Infect Dis 5:S21–S31PubMed

17.

Paul M, Soares-Weiser K, Leibovici L (2003) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J 326:1111–1119CrossRef

18.

Feld R (1999) Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 29:503–507PubMedCrossRef

19.

The EORTC International Antimicrobial Therapy Cooperative Group (1987) Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317(27):1692–1698CrossRef

20.

Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214PubMedCrossRef

21.

Marr KA (2002) Empirical antifungal therapy—new options, new tradeoffs. N Engl J Med 346:278–280PubMedCrossRef

22.

Corey L, Boeckh M (2002) Persistent fever in patients with neutropenia. N Engl J Med 346:222–224PubMedCrossRef

23.

Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14PubMedCrossRef

24.

Maertens J, Theunissen K, Verhoef G et al (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41:1242–1250PubMedCrossRef

25.

Klastersky J (2004) Antifungal therapy in patients with fever and neutropenia: less empirical and more rationale? N Engl J Med 351:1445–1447PubMedCrossRef

26.

Klasterky J, Paesmans M (2006) Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection. Support Care Cancer (in press, online publication September 12)

Title: Risk-adapted strategy for the management of febrile neutropenia in cancer patients
Authors: Jean Klastersky
Marianne Paesmans
Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles
Publication date: 01-05-2007
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 5/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0185-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Results and discussion

Please log in to get access to this content

Other articles of this Issue 5/2007

Clinicians’ practice and attitudes toward cancer pain management in Korea

The relationship between dyspnea and patient satisfaction with quality of life in advanced cancer

Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain

Impact of family structure on long-term survivors of osteosarcoma

Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies

Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer